Skip to main content

Table 4 Cox proportional regression analysis of the associations between patient characteristics and OS in all 6031 NPC patients

From: A new prognostic histopathologic classification of nasopharyngeal carcinoma

Characteristic

Patients [cases (%)]

OS rate (%)

Unadjusted HR

95% CI

P value

Adjusted HRa

95% CI

P value

5-year

95% CI

Proposed classification

 EC

3708 (61.5)

79.4

78.1–80.8

1.00

Reference

 

1.00

Reference

 

 MSEC

1247 (20.7)

70.5

67.7–73.0

1.48

1.32–1.67

<0.001

1.44

1.27–1.62

<0.001

 SC

823 (13.6)

59.6

55.9–63.1

2.16

1.90–2.44

<0.001

2.00

1.76–2.28

<0.001

 SCC

253 (4.2)

42.6

35.8–49.3

3.56

2.96–4.28

<0.001

4.23

3.34–5.38

<0.001

Age

 ≤47 years

3163 (52.5)

77.8

76.3–79.3

1.00

Reference

 

1.00

Reference

 

 >47 years

2868 (47.5)

68.4

66.6–70.2

1.54

1.40–1.70

<0.001

1.50

1.36–1.65

<0.001

Sex

 Male

4468 (74.1)

71.7

70.3–73.1

1.00

Reference

 

1.00

Reference

 

 Female

1563 (25.9)

78.1

75.8–80.2

0.73

0.65–0.81

<0.001

0.76

0.68–0.86

<0.001

Therapeutic modality

 Radiotherapy alone

2739 (45.4)

71.4

69.6–73.1

1.00

Reference

 

1.00

Reference

 

 Radiochemotherapy

3292 (54.6)

75.2

73.4–76.8

0.88

0.79–0.97

0.009

0.65

0.59–0.72

<0.001

Clinical stage

 I

177 (2.9)

92.4

87.1–95.5

1.00

Reference

 

1.00

Reference

 

 II

1041 (17.3)

85.6

83.2–87.6

2.20

1.27–3.79

0.004

2.25

1.3–3.89

0.003

 III

2424 (40.2)

74.3

72.4–76.0

4.17

2.46–7.08

<0.001

4.70

2.76–7.98

<0.001

 IV

2389 (39.6)

64.9

62.7–67.0

5.77

3.40–9.78

<0.001

6.96

4.09–11.85

<0.001

WHO classification

 NKUC

4871 (80.8)

73.8

72.5–75.1

1.00

Reference

 

1.00

Reference

 

 NKDC

1050 (17.4)

73.2

70.1–75.9

1.02

0.90–1.16

0.729

1.00

0.87–1.16

0.980

 KSCC

110 (1.8)

57.5

47.0–66.6

1.85

1.38–2.47

<0.001

0.51

0.35–0.74

<0.001

  1. OS overall survival, NPC nasopharyngeal carcinoma, HR hazard ratio, CI confidence interval, EC epithelial carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SC sarcomatoid carcinoma, SCC squamous cell carcinoma, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC non-keratinizing differentiated carcinoma, KSCC keratinizing squamous cell carcinoma
  2. a All models were adjusted for the proposed classification, age, sex, therapeutic modality, clinical stage, and WHO classification